Fundraising Fox

Hemotune

Founded 2017 · 32 employees on LinkedIn · 1 known investors

hemotune develops a magnetic nanoparticle platform for targeted magnetic separation in medical and biomanufacturing applications. The platform removes disease triggers and harmful agents from the bloodstream or processes biological materials with high selectivity and scalability.

BiotechDeep TechMedical Devices

Investors · 1

OCCIDENTMunich

Funding

SEC filings, press & company announcements
  • Undisclosed amountSeries B2Mar 2024 · 2 sources

    Belmondo (lead), EFI, HEMEX, OCCIDENT, VP Venture Partners, ZKB

    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

2 people who came through Hemotune went on to found or lead other companies.

Harald Casebourne StockPresident of the Board of DirectorsFounded DomusdxMonika DenglerSenior R&D Scientist - BiomedicineFounded Enantios

In the news

Hemotune Secures CHF 14 Million for Clinical Trials - The Swiss Timestheswisstimes.ch · Mar 2024Hemotune raises 14 million Swiss francs - Swiss Tradeswisstrade.com · Mar 2024hemotune raises CHF 14 million Series B2 funding for clinical trials with the HemoSystem | Hemotunehemotune.com · Mar 2024Hemotune raises CHF 7.25 million to develop blood purification platform – Swiss Biotechswissbiotech.org · Apr 2022Hemotune raises CHF 14 million with Belmondo, VP Venture Partners, Occident, Hemex and EFI Lake Geneva Ventures | Nordic 9nordic9.com

Frequently asked questions

What does Hemotune do?
hemotune develops a magnetic nanoparticle platform for targeted magnetic separation in medical and biomanufacturing applications. The platform removes disease triggers and harmful agents from the bloodstream or processes biological materials with high selectivity and scalability.
Who are Hemotune's investors?
Hemotune's investors include OCCIDENT.